Zacks Analyst Interview Highlights: Onyx Pharmaceuticals, ZymoGenetics, Eurand N.V., Myriad Genetics and BioMarin

Business Wire, Jan 25, 2008

CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Onyx Pharmaceuticals (Nasdaq: ONXX), ZymoGenetics Inc. (Nasdaq: ZGEN), Eurand N.V. (Nasdaq: EURX), Myriad Genetics (Nasdaq: MYGN) and BioMarin Pharmaceuticals, Inc. (Nasdaq: BMRN).

A synopsis of today's Analyst Interview is presented below. The full article can be read at http://at.zacks.com/?id=2678.

Do you have any top Buy recommendations for us today?

My top picks of biotech companies are Onyx Pharmaceuticals (Nasdaq: ONXX), ZymoGenetics Inc. (Nasdaq: ZGEN), Eurand N.V. (Nasdaq: EURX), Myriad Genetics (Nasdaq: MYGN) and BioMarin Pharmaceuticals, Inc. (Nasdaq: BMRN).

Do those companies you recommend all have something in common - low debt levels, far-reaching platforms, that sort of thing?

The companies I recommended above do have something in common. All of the above companies have approved products on the market. ONXX has Nexavar approved for kidney cancer and liver cancer. ZGEN has rhThrombin approved for hemostasis in surgical procedures. BioMarin has three products for rare genetics disorders and MYGN has very lucrative preventive medicine business. In EURX's case, the company does not have its own products approved for sale, but it earns product royalties from its partners. These approved products provide revenue for the company and provide funds for further drug research and development.

Another thing in common among the above companies is that all companies have a decent pipeline for long-term growth. This is important for a biotech company in the long run. When product patent expires or product sales mature, the company needs new drivers for growth. A decent pipeline assures such drivers will materialize in the future when old product sales stall.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

About Zacks

The performance of the Zacks Rank portfolios for annual and year-to-date periods are the linked monthly total returns (price changes dividends) of equal weighted hypothetical portfolios, consisting of those stocks with the indicated Zacks Rank, assuming monthly rebalancing and zero transaction costs. These are not the returns of actual portfolios. The hypothetical portfolios were created at the beginning of each month from January 1988 forward based on the values of the Zacks Rank available to Zacks' clients before the beginning of each month. The portfolios created monthly from 1988 through September 2006 exclude ADRs and are comprised of stocks that have the indicated Zacks Rank and were covered by at least two analysts at the time of the stocks inclusion in the portfolio. Starting in October 2006 and going forward, the portfolios are comprised of all stocks with the indicated Zacks Rank and do not exclude ADRs, which is more reflective of the list of stocks that customers will find on the Zacks web sites. These performance numbers have been audited from 1995 through 2003 by Virchow, Krause & Company, LLP.